» Articles » PMID: 24418295

Diagnostic Criteria of Autoimmune Hepatitis

Overview
Journal Autoimmun Rev
Publisher Elsevier
Date 2014 Jan 15
PMID 24418295
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disorder characterised by female preponderance, elevated transaminase and immunoglobulin G levels, seropositivity for autoantibodies and interface hepatitis. Presentation is highly variable, therefore AIH should be considered during the diagnostic workup of any increase in liver enzyme levels. A set of inclusion and exclusion criteria for the diagnosis of AIH have been established by the International Autoimmune Hepatitis Group (IAIHG). There are two main types of AIH: type 1, positive for anti-nuclear (ANA) and/or anti-smooth muscle antibodies (SMAs) and type 2, defined by the presence of anti-liver kidney microsomal antibody type 1 (LKM-1) and/or anti-liver cytosol type 1 (LC-1) autoantibodies. The central role of autoantibodies in the diagnosis of AIH has led the IAIHG to produce a consensus statement detailing appropriate and effective methods for their detection. Autoantibodies should be tested by indirect immunofluorescence at an initial dilution of 1/40 in adults and 1/10 in children on a freshly prepared rodent substrate that includes kidney, liver and stomach sections to allow for the simultaneous detection of all reactivities relevant to AIH. Anti-LKM-1 is often confused with anti-mitochondrial antibody (AMA) if rodent kidney is used as the sole immunofluorescence substrate. The identification of the molecular targets of anti-LKM-1 and AMA has led to the establishment of immuno-assays based on the use of the recombinant or purified autoantigens. Perinuclear anti-nuclear neutrophil antibody (p-ANNA) is an additional marker of AIH-1; anti soluble liver antigen (SLA) antibodies are specific for autoimmune liver disease, can be present in AIH-1 and AIH-2 and are associated with a more severe clinical course. Anti-SLA are detectable by ELISA or radio-immuno-assays, but not by immunofluorescence. AIH is exquisitely responsive to immunosuppressive treatment, which should be instituted promptly to prevent rapid deterioration and promote remission and long-term survival.

Citing Articles

Inflammatory bowel disease and risk of autoimmune hepatitis: A univariable and multivariable Mendelian randomization study.

Chi G, Pei J, Li X PLoS One. 2024; 19(6):e0305220.

PMID: 38848323 PMC: 11161122. DOI: 10.1371/journal.pone.0305220.


Regulatory T-cell deficiency leads to features of autoimmune liver disease overlap syndrome in scurfy mice.

Yilmaz K, Haeberle S, Kim Y, Fritzler M, Weng S, Goeppert B Front Immunol. 2023; 14:1253649.

PMID: 37818371 PMC: 10561387. DOI: 10.3389/fimmu.2023.1253649.


Autoantibody profile in sarcoidosis, analysis from the GRADS sarcoidosis cohort.

Khassawneh B, Zhu C, Barkes B, Vestal B, Shrock S, Gillespie M PLoS One. 2022; 17(10):e0274381.

PMID: 36264970 PMC: 9584415. DOI: 10.1371/journal.pone.0274381.


Rational development and application of biomarkers in the field of autoimmunity: A conceptual framework guiding clinicians and researchers.

Kolev M, Horn M, Semmo N, Nagler M J Transl Autoimmun. 2022; 5:100151.

PMID: 35309737 PMC: 8927991. DOI: 10.1016/j.jtauto.2022.100151.


Antinuclear antibodies (ANA) as a criterion for classification and diagnosis of systemic autoimmune diseases.

Andrade L, Damoiseaux J, Vergani D, Fritzler M J Transl Autoimmun. 2022; 5:100145.

PMID: 35128372 PMC: 8804266. DOI: 10.1016/j.jtauto.2022.100145.